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INTRODUCTION 
The relief of pain during surgery is the raison d’etre of 
anaesthesia. The international association for the study of pain has 
defined “pain is an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage”. Pain is always 
under estimated and under treated.
Analgesia,  one  of  the  components  of  triad  of 
anaesthesia,  has  now  extended  to  relief  of  post  operative  pain, 
chronic  pain  and  cancer  pain.  It  is  achieved  by  use  of  drugs 
administered through different routes and techniques among which 
the spinal route of analgesia plays an important role in the intra and 
post  operative  period.  Effective  postoperative  analgesia  reduces 
post operative morbidity allows early ambulation and discharge. 
The spinal cord has taken the center stage in analgesia 
practice following the demonstration of analgesia with intrathecal 
morphine by Yaksh and Rudy (1977). Deposition of drugs in the 
epidural and subarachnoid space paved a new era for pain relief.
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HISTORY
 Melzack and walls (1965) propounded the gate control theory 
of pain.
 Reynolds (1969) described the endogenous neuronal system 
of analgesia.
 Pert  and  Synder  (1973)  discovered  the  opioid  specific 
receptors in the substantia gelatinosa of spinal cord and brain.
 Martin  and  coworkers  have  classified  the  opioid  receptors 
into three types.
 Wang et al (1979) first applied intrathecal opioids for relief 
of pain.
 Michael  J.  Cousins  et  al  (1979)  demonstrated  the  use  of 
epidural morphine for analgesia.
 Glynn et al 1981 studied the pharmacokinetics and analgesic 
response of epidural meperidine in man.
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AIM OF THE STUDY
To  compare  the  effects  of  epidural  Nalbuphine  and 
0.5% Bupivacaine with that of 0.5% Bupivacaine alone in infra 
umbilical surgeries with respect to: 
• Onset of sensory blockade
• Onset of motor blockade
• Post operative analgesia 
• The quality of analgesia
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ANATOMICAL CONSIDERATIONS
The epidural space is a potential space within the bony cavity 
of  the  spinal  canal  and  outside  dural  sac.   It  extends  from the 
foramen magnum to the coccyx.  Within the cranium the endosteal 
and meningeal layers are united but below the foramen magnum 
the two layers are separate, the outer becoming the periosteal lining 
of  the  spinal  canal  duramater.   Between  these  2  layers  lies  the 
epidural space.  The spinal canal is triangular in cross-section and 
the epidural space is widest in midline posteriorly in the lumbar 
region averaging about 5-6mm in diameter.   In the mid thoracic 
region the distance is somewhat less in the range of 3-5mm in the 
midline.
BOUNDARIES OF EPIDURAL SPACE 
Above  : the foramen magnum where the periosteal and 
spinal layers of the dura fuse together.
Below  :  the sacrococcygeal membrane
Front  : the posterior longitudinal ligament covering the 
posterior  aspect  of  vertebral  bodies  and 
intervertebral disc.
Behind : the anterior surface of vertebral lamina and 
ligametum flavum
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Laterally : the  pedicles  of  vertebra  and  intervertebral 
foramina with the paravertebral spaces.  Fibrous strands anchoring 
the dura posteriorly, party divides the epidural space in the midline 
so that injected fluid frequently divides the space laterally rather 
than in the midline.
Ligamentum  flavum is concerned with the identification of 
the epidural space.  It is composed of yellow elastic fibres.  It is 
thinnest in the cervical region becoming thicker lower down. The 
spine is thickest in the lumbar region.
SIZE OF THE EPIDURAL SPACE
REGION EPIDURAL SPACE THICKNESS OF DURA
Cervical 1 - 1.5 mm 1.5 - 2mm
Upper thoracic 2.5 - 3 mm   1 mm
Lower thoracic 4 - 5 mm   1 mm
Lumbar 5 - 6 mm     0.66 - 0.33 mm
CONTENTS OF THE EPIDURAL SPACE
It includes dural sac and spinal nerve roots, extra dural plexus 
of  veins  (Batson’s)  lymphatics  and  fat.   The  31  pairs  of  spinal 
nerves  with  their  dural  cuff  traverse  the  space  on  their  way  to 
intervertebral  foramina.   The  veins  receive  tributaries  from  the 
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adjacent bony structures and the spinal cord.  They communicate 
with the venous rings at each vertebral level with the basivertebral 
veins in the posterior aspect of each vertebral body and with the 
ascending, deep cervical, intercostals, ileo lumbar and lateral sacral 
veins.   The  veins  have  no  valves  and  constitute  the  valveless 
vertebral venous plexus of Batson.
They  connect  the  pelvic  veins  below with  the  intracranial 
veins above,  so that  air  or  local  analgesic solution injected may 
ascend to the  brain.   They drain into interior  vena cava via  the 
azygos vein.
The epidural  veins  become distended during coughing and 
straining  and  when  inferior  vena  cava  is  obstructed  or  in  late 
pregnancy.   The  intrathoracic  pressure  is  conducted  via  the 
paravertebral  space  to  the  thoracic  epidural  space  and  to  a 
diminishing extent to the cervical and lumbar region.
ANATOMY OF THE LUMBAR VERTEBRA
The  bodies  of  the  lumbar  vertebra  are  large  and  kidney 
shaped, the vertebral foramen in roughly triangular.  The pedicles 
are thick with shallow superior notches.  The transverse processes 
are  slender  the  laminae  are  short,  broad  and  strong  and  do  not 
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overlap  each  other.   The  spinous  processes  are  horizontal  and 
oblique.
LOCATION OF SPINAL SEGMENTS IN RELATION TO THE 
VERTEBRAE
SPINAL CORD      SEGMENT         VERTEBRAL LEVEL
Cervical 1-8 cervical 1-7
Thoracic 1-4 thoracic1-3
thoracic 5-12 thoracic4-10
Lumbar 1-5 thoracic T10-12
Sacral 1-5& coccygeal      lower half ofT12-L1
IDENTIFICATION OF EPIDURAL SPACE
In 1921 fidel pages identified the lumbar epidural space with 
the “ sense of give” that is felt by the operator when the needle 
escapes from the tough ligamentum flavum and enters the epidural 
space.
The  current  methods  of  identifying  the  lumbar 
epidural space fall into 2 groups. Those dependent on
1) loss of resistance to injection
2) The negative pressure in the epidural space.
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I Loss of resistance of injection – the test of Sicard, Forestier 
and Dogliotti:
This technique is based on the fact that there is a considerable 
loss of resistance to injection through the needle as it advances the 
tough ligamentum flavum into epidural space. Either a liquid filled 
or air filled system can be used to identify this loss of resistance.
Various  mechanical  aids  can  be  used  to  facilitate  the 
appreciation of loss of resistance namely.
i) Macintosh’s needle with spring loaded stylet. 
ii) Brunner and like’s spring loaded syringe.
iii) Macintosh’s balloon indicator.
iv) Zelenka’s ‘U’ tube and balloon indicator.
II. Negative pressure sign:
A negative pressure is present in 80% of the lumbar epidural 
spaces. The reasons for it are
i) An artifact created by indentation of the dura with the advancing 
needle
ii) Flexion of the spine
iii)  Transmission  of  the  negative  intrapleural  pressure  via  the 
paravertebral spaces to the epidural space.
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Negative pressure in the epidural space is not the same at all 
levels. In the sacral canal it is absent and it is lower in the thoracic 
region than in the lumbar part of the space.
This negative pressure can be appreciated by:
Hanging Drop sign of Gutierrez.
The epidural needle is placed in the interspinous ligament and 
a drop of fluid is placed in the hub of the needle. As the needle is 
advanced into the epidural space, due to the negative pressure, fluid 
is sucked in.
Various  mechanical  aids  can  be  used  to  identify  this  negative 
pressure namely.
i) ‘U’ tube manometer
ii) Aneroid manometer
iii) Zorrauin’s Bulb indicator
iv) Odom’s indicator
v) Brook’s indicator
vi) Zelenka’s balloon indicator
vii) Dawkin’s gravity indicator
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Mechanism of action of drugs injected into epidural space:
The precise mode of action of an epidural analgesia remains 
to be totally  explained.  Theories of mechanism of action,  centre 
around one or more of the following sites.
i) Mixed spinal nerves in the paravertebral space.
ii) Dorsal root ganglia.
iii) Spinal roots within the dural root sleeves.
iv) Subpial region.
Possible sites of action:
i) Paravertebral block – probably non-essential.
ii) Intradural  spinal  roots  –  probably  the  principal  and 
essential site of action. 
iii) Spinal cord – blocked subsequent to blockade of nerve 
roots.
DISTRIBUTION OF THE DRUG GIVEN INTO THE 
EPIDURAL SPACE
         Following epidural injection, the longitudinal spread depends 
on  the  remaining  volume  of  solution,  since  some  volume  is 
expected to leak out of the epidural space. Some of this penetrate 
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the epineurium and perineurium into the sub perineural space. This 
then  spreads  subpially  to  reach  the  neuraxis.  Hence  vascular 
mechanisms are involved in the neural uptake. High concentrations 
of  local  anaesthetics  in  the  intradural  roots  suggests  dural  root 
sleeves with arachnoid granulations are likely to be the principal 
site of penetration through the dural barrier.
          From the dural sleeves, the drug spreads in the subdural 
space with further penetration into subarachnoid and subpial space 
from where the local anaesthetics enter into the nerve roots and the 
spinal crod.
FACTORS  AFFECTING  THE  SPREAD  OF  THE  LOCAL 
ANAESTHETIC:
1. Age
         Dose requirements rise steeply during the period of growth 
and maturation and when the body growth has reached its limits the 
opposing effects of senescence become unmasked and there is a 
progressive reduction in the dose requirements as age advances.
          The increase in dose during maturation is due to
(i) Expanding spinal cylinder
(ii) Increased binding site
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The decrease in dose requirement during old age is due to 
i) Impaired tissue barriers
ii) Reduction in the number of binding sites
iii) Declining neuronal population
ii. Height of the individual
Volume of  the  epidural  space  is  proportional  to  its  length 
which is  related to  body height.  As per  a  study by Bromage in 
1962,  there  is  a  tendency  towards  increasing  dose  requirements 
with increasing height. But the statistical association is weak. Thus 
while the length of the spinal cylinder can be taken into account 
when the dosage requirements are being computed, for all practical 
purposes, it can be ignored except in extremely short and extremely 
tall.  For  bupivacaine  0.5%,  it  has  been  advocated  to  use 
1ml/segment  to  be  blocked  for  150cm  (5ft.)  of  height  plus. 
1ml/segment for each 5cm over 150cm.
iii. Atherosclerosis:-
In  atherosclerotic  individuals,  the  dosage  requirements  are 
reduced much below the predicted chronological level. The same 
dosage level results in a 40-50% increase in the segmental spread. 
The latency of onset is delayed by 35%.
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This is due to
i) Prematurely declining neuronal population.
ii) Changes in the ground substance.
iv. Increased intra abdominal pressure:
The dosage requirements have to be reduced by about 33%. 
This is due to diversion of a proportion of venous return through 
the internal vertebral venous plexus which become engorged and 
thus reducing the volume of the epidural space thereby increasing 
the spread.
v. Site of injection:-
The drug preferentially acts in the segments close to the site 
of injection. Hence it is suggested to give the drug in the mid space 
of the desired blockade.
vi. Speed of injection:
With rates between 0.3ml/sec to .75ml/sec, the spread is the 
same.  Abnormally  faster  and slower  rates  are  likely  to  alter  the 
spread of epidural solution.
vii. Posture:
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There  is  slight  but  significant  difference  between  dosage 
requirements in patients sitting and supine. Since gravity favours 
downward  spread,  it  is  worthwhile  to  exploit  gravity  to  favour 
spread. However the magnitude of influence is not great.
viii. Volume concentration and composition of local anaesthetic 
solution:
Increasing dosage produces a linear increase in the duration 
of sensory block.
Increasing  the  concentration  reduces  the  onset  time  and 
increases the intensity of block.
Increasing  the  volume  injected  increases  the  longitudinal 
spread of solution and also the duration of block.
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PHYSIOLOGICAL CONSIDERATIONS
There are two components of pain, neurophysiologically 
mediated sensory component and an emotional component.
There are two types of pain
1. Physiological  pain  is  a  transient  sensation  due  to  noxious, 
mechanical, thermal, chemical stimulus each with a clearly defined 
threshold and without causing damage to the nervous system.
2. Pathological pain is an inflammatory response to tissue injury or 
damage to central nervous system with an alteration in perception. 
Pain following surgery is pathological
There are two major theories of pain:
1. SPECFICITY THEORY proposed by Von Frey states the pain is 
due to stimulation of specific end organs.
2. INTENSIVE  SUMMATION  pattern  theory  proposed  by  Gold 
Scheider states  that  there are no specific  pain receptors and any 
sensory stimulus if sufficiently severe would produce pain.
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ORGANISATION OF PAIN PATHWAYS
According  to  the  recent  theory  pain  pathway  is  organized  as 
follows.
Receptors:  Nociceptive receptors are fine, profusely branched, free 
nerve endings covered by Schwann cells with little or no myelin.  
There are three types of receptors:
1. Mechano-sensitive nociceptors activated by mechanical stimuli
2. Mechano thermal nociceptors activated by mechanical and thermal 
stimuli more than 43 degree Celsius 
3. Polymodal  pain  receptors  respond  to  mechanical,  thermal  and 
chemical  stimuli  like  hydrogen  and  potassium  ions,  histamine, 
serotonin, bradykinin, prostaglandins, substance P.
FIRST ORDER NEURONS
Mechanosensitive  and  mechano-  thermal  pain  receptors 
transmit impulses through thinly myelinated Adelta fibres of 1-5 
micrometer  diameter  with  conduction  velocity  of  15-30mts  per 
second.  This is responsible for fast pain which is sharply localize. 
Polymodal pain receptors transmit impulses through unmyelinated 
C fibres of 0.4-1.1 micrometer diameter with conduction velocity 
of  0.5-2  meter  per  second.   This  is  responsible  for  the  poorly 
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localized slow pain.  Transmission through both these fibres causes 
the  “Double  response  of  Lewis”.   The  peripheral  afferent  fibres 
have their cell body in the dorsal root ganglion and project via the 
lateral  part  of  the  dorsal  root  called  “Tract  of  Lissauer.   They 
terminate in dorsal horn of spinal cord with 1-2 segments of entry. 
A  delta  fibres  terminate  in  lamina  1  (marginal  cell  layers  of 
Waldeyer) and lamina 5 (wide dynamic range of neurons which 
respond to their modalities also).  Un myelinated c fibres terminate 
in lamina 2&3 (substantia gelatinosa)
SECOND ORDER NEURONS
They arise from the cells and connect with ventral and lateral 
horn cells in the same and adjacent spinal segments and sub serve 
both somatic and autonomic reflexes.  About 75% of other sensory 
neurons  project  contra  laterally  after  decussating  in  the  anterior 
commissure 1-3 segments higher than the root of entry and divide 
into 2 descending tracts.
NEO SPINOTHALAMIC-LATERAL SPINOTHALMIC TRACT
It  ascends  in  the  antero lateral  funiculus  of  spinal  cord to 
brain stem and thalamus and contains fast conducting fibers which 
transmit specific localized pain.  The fibres are arranged in such a 
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way that fibres from lower part of body are superficial and from 
upper art of the body are inner most.
PALEOSPINOTHALAMIC-VENTRALSPINOTHALAMIC-
TRACT:
It  is  medially  placed and contains slowly conducing fibres 
responsible for ”second pain” and has connections with reticular 
core of brain stem limbic and subcortical regions.
AUXILLARY PAIN CONDUCTING PATHWAYS:
Thalamic in the nucleus ventro postero lateralis which is the 
major  sensory  relay  nucleus.  The  other  fibres  terminate  in  the 
posterior  group  of  nuclei  which  includes  nucleus  ventralis 
posteromedialis,  intralaminar  nuclei,  ventrobasal  complex  and 
hypothalamic nuclei.
THIRD ORDER NEURONS
Posterior  thalamic nuclei  project  to  the  post  central  cortex 
and  upper  bank  of  sylvian  fissure  and  sub  serve  tactile  and 
proprioceptive stimuli with discriminative sensory function.
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Perception of pain :
The threshold of perception of pain is the lowest intensity of 
stimulus  recognized  as  pain.  The  conscious  awareness  or 
perception  of  pain  occurs  when the  thalamo cortical  pathway is 
destroyed.   Somato  sensory  cortex  is  essential  for  the  accurate 
localization,  appreciation  of  intensity  and  other  discriminative 
aspects  of  pain.   Prefrontal  cortex  subserves  the  unpleasant 
affective and emotional reaction to pain.
GATE CONTROL THEORY OF PAIN :
It was propounded by Melzack and Walls in 1965. It states 
that  modulation  of  pain  transmission  via  the  spinothalamic  tract 
through the stimulation of large afferent fibres excite the inhibitory 
cells in laminar 2 & 3 of dorsal horn which in turn cause pre and 
post synaptic inhibition of secondary transmission neurons (T cells) 
in lamina 5 of dorsal horn and interrupt pain pathway.  Conversely 
stimulation of small pain afferents (c fibres) inhibit the T cells in 
the excitatory state thus facilitating transmission of pain.
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CENTRAL SENSITISATION OR WIND UP
Prolong nociceptive stimulations leads to hyperexcitability of 
dorsal horn cells and increased cephalad transmission resulting in 
increased  pain  sensation.   This  is  responsible  for  chronic  pain 
syndromes.  Descending inhibiting pathways and endogenous pain 
control mechanisms.  It extends from the hypothalamus along the 
periventriculars  and  periaqueductal  grey  matter  which 
communicate through dorso lateral funiculus to end in the nucleus 
raphe magnus and locus caeruleus.   Stimulation anywhere along 
this tract releases endogenous opioid like peptides and endorphins 
which  activate  serotoninergic  pathway  via  descending 
reticulobulbar spinal system and interact with lamina 1 and 2 of the 
dorsal horn and exert   analgesia.  Another descending inhibitory 
pathway arises from locus caeruleus in pons and projects directly to 
the spinal cord.  Here neurotransmitter is nonadrenaline and this 
pathway  inhibits  pain  responses  in  spinal  cord  by  alpha  2 
adrenergic mechanism.
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ENDOGENOUS  OPIOIDS  AND  OTHER  NEURO 
TRANSMITTER  AND  SPINAL  MODULATION  OF  PAIN 
PERCEPTION.
There  are  5  endorphins.   Metenkephalin,   leuenkephalins, 
betaendorphin, alpha endorphin and R endorphin.  
METENKEPHALIN AND LEUENCEPHALIN:  
They  are  inhibitory  neurotransmitters  at  the  site  where 
primary processing of  afferent  nociceptive information occurs  in 
laminar 1,2,5 of dorsal horn.  They act through release of substance 
P.Dynorphins: Control nociception at the spinal cord level through 
activation of kappa receptors.  It is present in lamina1-5 of dorsal 
horn.
BETA-ENDORPHINS
It is a fragment of the pituitary hormone of beta-lipotropin.  It 
activates  descending serotoninergic  pathways and suppresses  the 
nociceptive response of spinothalamic neurons.  It acts on epsilon 
receptors and modulates nociceptors during stress.
L-endorphins and R – endorphins are breakdown products of beta 
endorphins.
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SUBSTANCE  P  (substance  preparation)  it  is  a  II  amino  acid 
peptide.  It acts on excitatory transmitter in laminar 1,2,4 and 5 of 
dorsal horn, spinal trigeminal nucleus and type B cells in dorsal 
root ganglia.  It is released in vivo by the activity of Adelta and C 
fibres.  Endogenous opiates inhibit presynaptic pathway inhibit the 
action of substance P at the post synaptic level thus inhibiting pain 
transmission. 
SOMATOSTATIN :
It is a 13 aminoacid peptid found in lamina 2 of dorsal horn 
and inhibits function of afferent pain fibres.
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PHARMACOLOGICAL CONSIDERATIONS
Opioid  receptors:  Stereospecfic  binding  sites  called 
receptors for opioid drugs are present in the cortex, limbic system, 
hypothalamus,  medial  thalamus,  periaqeductal  grey  matter, 
substantia gelatinons.  High density of opioid receptors are present 
in the substantia gelatinosa at the presynaptic and post synaptic site 
of C delta and C fibre input.  Martin and coworkers have classified 
opiod  receptors  in  to  5  major  groups  Mu  (Mu1,  Mu2)  kappa 
(k1,k2,k3) sigma, delta, epsilon.  Mu 1 receptor causes supra spinal 
analgesia and delta  causes spinal  analgesia on stimulation kappa 
receptors of which k1 causes spinal analgesia and k3 supra spinal 
analgesia.
NALBUPHINE
Chemistry: 
Nalbuphine hydrochloride is an agonist-antagonist analgesic 
synthesized in 1965.  It  is structurally related to the pure agonist 
oxymorphone and the pure antagonist naloxone.
Pharmacokinetics: 
Mechanism of Action:
Nalbuphine binds readily to both mu – and kappa receptor. 
29
Action on mu – receptor has Antagonist effects. 
Action on kappa –  receptor  has  Agonist  effects  which produces 
analgesia. 
Dosage:
Maximum single dose : 20mg / dose
Maximum total daily dose : 160 mg/day
Absorption:
Nalbuphine  administered  parentrally  (intramuscular/intravenous/ 
subcutaneous)
Onset and Duration
Onset 
Intravenous : within 2 – 3 minutes
Intramuscular and subcutaneous: Less than 15 minutes
Duration:
Single dose : 3 to 6 hours
Time to peak concentration:
Intravenous : Peak effects seen within 30 minutes
Intramuscular: 0.48 to 0.63 hour
Subcutaneous: 0.44 to 0.48 hour
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Distribution:
Nalbuphine is not bound to plasma protein.
Nalbuphine crosses the placenta.
Metabolism
It  undergoes  hepatic  metabolism  to  pharmacologically  inactive 
conjugates. Both unchanged drug and conjugates are secreted into 
bile.
Excretion
Major route of elimination is fecal with little renal elimination (7%)
Indication:
Relief of moderate to severe pain.
Preoperative and post operative analgesia.
Supplement to balanced anaesthesia. 
Administration:
Recommended  dose:  10mg/  70  kg  adult  can  be  administered 
IV/IM/SC. Dosage should be administered according to severity of 
pain, physical status of patients & other medications. 
Cautions:
A) Contraindications:
Hypersensitive to Nalbuphine or any ingredients of the preparation.
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B) Precautions:
Impaired respiration – (Bronchial Asthma)
Impaired renal / hepatic function
Myocardial infarction
Coma,  head  injury,  intracranial  lesion,  or  increased  intracranial 
pressure. 
PHARMACODYNAMIC ACTION
The safety and efficacy of nalbuphine as an analgesic 
for  the  management  of  moderate  to  sever  pain  have  been 
documented  by  several  studies.  In  chronic  pain  studies  with 
orthopedic and cancer patients, the analgesic effect of nalbuphine is 
comparable  with  that  of  morphine  on  a  milligram to  milligram 
basis without overt evidence of development of physical tolerance.
Use of nalbuphine in acute postoperative pain indicates 
that  the  drug  is  equipotent  to  or  only  slightly  less  potent,  than 
morphine. As preoperative medication nalbuphine and morphine in 
doses of 0.1 and 0.15 mg kg-1 respectively, are equianalgesic. In 
analgesic supplemented (balanced) anaesthesia,  nalbuphine offers 
several advantages over morphine –
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1. Cardiovascular stability.
2. Adequate postoperative ventilation
3. Rapid recovery of wakefulness.
4. lower incidence of nausea and vomiting.
5. Shorter stay in the recovery room.
Mean total dose requirements are usually 1mg-kg-1 (compared 
with  0.5  mg.kg-1  morphine)  with  a  range  of  0.5  to  3mg.kg-1. 
Parenteral nalbuphine is also effective in pain relief during labour, 
acute MI and a variety of medical conditions including renal and 
biliary colic.
Nalbuphine  in  doses  of  10  mg  per  70  kg  causes  respiratory 
depression approximately equal to that produced by a similar dose 
of morphine, but in contrast to morphine, respiratory depression is 
not  appreciably  increased  with  higher  doses  of  nalbuphine. 
Respiratory depression peaks or plateau at about 30 mg/70 kg with 
adequate  post  operative  ventilation,  following  the  intraoperative 
use  of  as  high  as  3mg.kg-1.  Naloxone  effectively  reverses  the 
respiratory depression but is rarely required.
IV nalbuphine is associated with hemodynamic stability when 
used for  cardiac  catheterization,  acute  myocardial  infarction  and 
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intraopertively.  A  stable  circulation  may  be  partly  related  to 
minimal  histamine  release  by  this  agent.  This  is  in  contrast  to 
morphine which liberates  measurable amounts of histamine.  The 
hemodynamic effects of nalbuphine differ from those of pentazoine 
and  butorphanol  which  increase  pulmonary  artery  pressure  and 
cardiac work load.
Chronic  administration  of  nalbuphine  produces  a  physical 
dependence  which  resembles  that  of  pentazocine,  since  it  has 
elements of both morphine and nalorphine dependence. Nalbuphine 
will  not  substitute for morphine in narcotic  depedent  individuals 
and  in  fact  will  precipitate  abstinence.  Studies  indicate  that 
nalbuphine has a relatively low abuse potential. Nalbuphine is not 
subject to narcotic control.
Nalbuphine may cause miosis which usually occur after the first 
dose.  In  one  study it  was  found that  nalbuphine  was about  one 
quarter  as  potent  as  nalorphine  as  an  antagonist  in  subjects 
dependent on 60 mg of morphine a day. It has also been used to 
reverse narcotic induced respiratory depression without reversing 
analgesia. Nalbuphine has no effect on the ECG, little effect on the 
EEG and no major effect on clinical laboratory test values. 
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Adverse Effects:
 10%  CNS:  Fatique,  drowsiness,  headache,  dizzness,  night 
mares, 
 1% to 10%: Histamine release
 CVS: Hypotension
 GIT: Anorexia, Nausea, Vomiting, dry mouth
 Local: Pain at the injection site
 Neuromuscular/Skeletal: Weakness
 < 1% bradycardia, tachycardia, pulmonary oedema, narcotic 
Neuromuscular/Skeletal: Weakness
 < 1% bradycardia, tachycardia, pulmonary oedema, narcotic 
withdrawal. 
The  drug  should  be  used  with  caution  in  emotionally 
unstable persons,  those with a history of narcotic abuse,  patients 
with  head  injury  or  elevated  intracranial  pressures  and  in  the 
presence of  ventilatory  renal  or  hepatic  dysfunction.  Nalbuphine 
dosage  should  be  reduced  when  other  central  nervous  system 
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depressant  drugs  are  administered.  It  has  not  been  extensively 
studied in children, pregnant women or during labour and delivery.
Oral  nalbuphine  (not  yet  commercially  available)  is 
about  one-third  as  potent  as  intramuscular  nalbuphine.  As  an 
analgesic supplement to balanced anesthesia, doses range from 0.5 
to 3mg.kg-1 with an average dose of 1 mg.kg-1.
BUPIVACAINE
Bupivacaine was synthesized in 1957 by Ekenstam and his 
colleagues and used clinically by Telivuo in 1963.
PHARMOKINETICS
It is a N-butyl pipecolic. 2,6 dimethyl xylidide hydrochloride
Molecular Weight 288
PKA 8.05 – 8.1.
Partition coefficient 27.5
Proteing Binding 95%
Specific gravity at 37oc = 0.998.
It is highly lipid soluble and has a potency of approximately 
four times that of lignocaine and mepivacaine. It is more protein 
bound and less  cumulative.  It  has a  longer latency and a longer 
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duration of action. It  appears to produce sensory analgesia more 
efficiently than motor block.
Metabolism:  After  systemic  absorption,  the  drug  is 
metabolized  in  the  liver  by  N-dealkylation  to  pipecoly  xylidine 
(ppx) which is approximately one eights as toxic as bupivacaine. 
PPX and unchanged bupivacaine are excreted  in equal proportions 
in the urine. The slow phase half life (t ) is about eight hours in the 
normal subjects.
Toxic level: Scott (1975) suggests that a venous concentration of 
2ug/ml gives rise to toxic effects when the drug is administered 
rapidly.
Mechanism of Action:
1. Bupivacaine  acts  directly  on the receptors  within the 
sodium channels of the nerve membrane.
2. Produces non-specific membrane expansion. 
Pharmacological effects
a) Local: Nerve Blockade
b) Regional: Pain, temperature, touch, motor power
and  vasomotor  tone  in  the  region  supplied  by  the  nerves  are 
blocked.
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c) Systemic:  Effects  occurring  as  a  result  of  systemic 
absorption.
Pharmodynamics 
i) CVS: Dose related
Heart:  Depresses  automaticity,  myocardial 
contractility and reduces cardiac sensitivity to adrenaline.
Gross  overdosage  produces  ventricular 
tachycardia, fibrillation and cardiac arrest.
ii) CNS: Sedation, light headedness, anxiety and restlessness 
Toxicity:  Circumoral  numbness  paraesthesia,  twitching,  visual 
disturbances,  convulsions  coma,  respiratory  and  cardiac 
depression.
iii) Neuromascular junction:
Blocks motor nerves and presynaptic junction.
iv) Hypersensitivity reaction: Rare.
Preparations available:
Epidural:
1. 0.125%  -  pain  relief,  high  failure  rate,  brief 
duration
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2. 0.25%  only  sensory  blockade,  motor  blockade 
poor
3. 0.5% successful sensory blockade with minimal 
motor blockade.
4. 0.75% adequate motor and sensory blockade.
Spinal
Hyperbaric: 0.5% & 0.75%
Isobaric: 0.5%
Maximal Dose:2mg/kg.
Carbonation and alkalinization:
Most of the clinically used adjuvants alter the physiochemical 
properties of local anaesthetics. Of this, one of them is adjusting the 
pH of local anaesthetic, by addition of sodium bicarbonate or the 
use of carbonated local anaesthetics.
It is the lipid soluble undissociated base form of the drug that 
penetrates  the  neural  membrance  to  reach  the  interior  of  the 
axoplasm ( Ritchie et al).35 The pharmacologic effect, blockade of 
nerve  conduction,  however,  is  produced  by  the  water  soluble 
dissociated cationic form. The degree of dissociation is determined 
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by the Henderson – Hasselbach equation and is dependent on the 
drug’s dissociation constant (pKa).
The pKa of commonly used local anaesthetics is between 7.7 
and  8.9.  Lignocaine  and  Bupicaine  have  a  pKa  of  7.9  and  8.1 
respectively.  Most  of  the  commercial  preparations  of  local 
anaesthetics are quite acidic ( pH ranging from 4.2 -6.5) to improve 
stability of the drug and thus prolong its shelf life. At this range of 
pH, less drug is available in the undissociated base form, which is 
required  to  transfer  across  the  perineural  sheath  and  neural 
membrane.  Agents  influencing the  degree  of  dissociation should 
therefore have an effect on the onset and degree of neural blockade.
However  upward  adjustment  of  pH  should  be  done  very 
carefully as excessive alkalinization causes the local anaesthetic to 
precipitate.  This  is  especially  common  with  bupivacaine  and 
etidocaine.
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REVIEW OF LITERATURE 
1.Romagnoli A. Keeats As 1980
Studied  the  ceiling  effect  for  respiratory  depression  by 
Nalbuphine and morphine and demonstrated that with higher doses 
of morphine respiratory impairment progress to apnoea, where as 
with  nalbuphine did not apnoea occur demonstrating the reversal 
effect.
2.  Dondoni  R,Rolly  G,Devulder  J,Verdonck  R,Acta 
Anaesthesiol Belg 1988;39(4):251-6
Compared Nalbuphine 20gm I.M. to pentazocine 30 mg I.M. 
for postoperative pain relief after orthopedic surgery.Onset duration 
and quality of pain relief were significantly superior for nalbuphine 
with  50%  of  the  obseravation  period.  Cardiovascular  and  side 
effect were in both group minor.
3. van den Berg AA, Honjol NM, Prabhu NV,Datta S, Rozario 
CJ,  Muarleedaran  R,Savva  D.  Department  of 
Anaestheesia,Riyadh Armed Forces Hospital,Kingdom of Saudi 
Arabia. Br J Clin Pharmacol 1994 Dec; 38 (6) : 533-43             
          To rationalize the choice of analgesic for routine ENT 
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surgery  they      examined  the  intraoperative,  recovery  and 
postperative  effect  following  the  administration  of  ethier 
buprenorphine (3.0 to 4.5 microgrms Kg-1), diclofenac(1 mg Kg-
1),  fentnyl(1.5 to 2.0 microgrms Kg-1),  morphine(0.1 o 0.15 mg 
Kg-1), nalbuphine(0.1 to 0.15 mg Kg-1), pethidine(1.0 to 1.5 mg 
Kg-1), or saline(as control) given with the induction of anaesthesia 
in 374 patients.Intraoperatively their effecs on heart rate and blood 
pressure,  airway  pressure  and  intraocular  pressure,  were  similar. 
Nalbuphine and pehidine produced sedation with analgesia during 
recovery, a prolong time to re-medication and mild emeic effect. 
4.  Jeon  SY,Lee  SH,  kwon  BY,  Koren  J  anesthesiol.1996 
Dec;31(6):764-770. Korean.
                Described the usefullness of the epidural injection of 
narcotics for the relief of postoperative pain. Morphine, a u-receptor 
agonist,  produce  strong  analgesic  effect  with  some  side 
effect.Nalbuphine,  is  a  mu-antagonist  and  kappa-agonist,  has  an 
anlagesic  effect  comparable  to  morphine  with  little  side 
effect.Nalbuphine hydrochloride could be better agent then morphine 
in term of complictation. 
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5. Khan FA, Zaidi A, kamal RS.
Anaesthesia.1997 Nov;52(11):1095-101.
            Evaluated the efficacy of Nalbuphhine and Buprenorphine in 
total intravenous anaesthesia. No difference was observed in blood 
pressure  but  the  heart  rate  was  significantly  lower  in  the 
buprenorphine  group.  intra-operative  bradycardia(heart  rate<60 
beat.min-1)  occurred  more  often  in  the  buprenorphine  group. 
Recovery was fast and comparable with both drugs and no patient 
reported awareness. Quality of analgesia was similar in both groups. 
Both  drugs  provide  suitable  analgesic  supplementation  and 
nalbuphine offers  useful alternative to buprenorphine .
6. Parker et l,1997.
              Assessed  the  analgesic  effect  of  Nalbuphine  with  
hydromorphone in post caesarean delivery.In a double bliend trial, 
78 women were given hydromorphone 0.075 mg/ml alone or with 
nalbuphine 0.02,0.04, or 0.08 mg/ml. 
                A mixture of hydromorphone and nalbuphine provided 
more effective PATIENT-CONTROLLED EPIDURAL ANALGESI 
43
with  fewer  side  effects  than  hydromorphone  alone  for  women 
recovering  from  caesarean  delivery.  Nalbuphine  produced  dose-
dependent decrease in urinary retention, itching, nausea and some of 
the typical opioid side effects were greatly reduced.
7. Anesth Anlg 1999;88:686
               compared Nalbuphine, Meperidine, and placebo for treating 
Postanesthetic Shivering. Ninety adult patients included in the study. 
Group  1received IV nalbuphine  0.08mg/kg,  Group  2  received  IV 
mepridine 0.4mg/kg, and Group 3 received IV saline. Treatment that 
stopped shivering was considered to have been successful. Results 
demonstrated that both nalbuphine and meperidine provide a similar 
rapid  and  potent  anti-shivering  effect.  Nalbuphine  may  be  an 
alternative to meperidine for treating postanesthetic shivering
8 .Khlid Maudood Siddiqui,Ursula Chohan (JPMA 57:67;2007).
             Compared the result of tramadol with Nalbuphine for 
dilatation  and  evacuation  with  total  intra-venous  anaesthesia 
technique. A total of 70 patients where included in this prospective, 
double blind randomized study. Intravenous tramadol 1.5mg/kg and 
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nalbuphine  0.1mg/kg  where  compared  in  total  intravenous 
anaesthesia  using  a  propofol  infusion  in  patients  undergoing 
dilataion and evacuation Change in haemodynamic variables greater 
then 20% from the base line values were noted. Quality of analgesia 
was  better  in  nalbuphine  group  but  both  drugs  provided  suitable 
analgesic supplementation .
9.Brock-Utne JG, Ritchie P,Downing JW.
               Compared the efficacy and impact on respiratory rate of 
Nalbuphine  and  pethidine  used  for  postoperative  pain  relief. 
Nalbuphine hydrochloride, a synthetic agonist-antagonist analgesic, 
in  a  dose  of  20mg  was  compared  with  pethidine  100mg  in  60 
patients after elective surgery in a random double-blind study. Both 
drugs were given intramuscularly on the first day after surgery  The 
result of study shown that nalbuphine had a long duration of action. 
There was significant respiratory depression with pethidine group.
10.Tammisto T, Tigerstedt I.
            Compared  the  analgesic  effect  of  Nalbuphine  and 
pentazocine  during  the  immediate  post  operative  period  after 
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abdominal surgery. The onse of pain relief was similar and the peak 
effect occurred about half an hour after the injection both drugs. On 
a  milligram basis,  Nalbuphine seemed to be  about  three  times as 
potent as pentazocine. The duration of action seemed to be slightly 
longer after nalbuphine, but 2 1/2hrs. after the injection the pain had 
returned to pre injection level in 2/3 of the patients, even after the 
higher doses of both drugs.  Except for sleepiness, there were few 
side  effect  and  they  were  similar  after  both  drugs.  No 
psychotomimetic effects were observed.
11.Hook PC, lvery KM.
              Compared the effect  and safety to  Nalbuphine and 
Pentazocine  with  midazolam  in  patients  undergoing  minor  oral 
surgery under local analgesia. Forty patients, aged between 17 and 
48 years and A.S.A.Class I prticipated. The results confirmed that 
the use of either nalbuphine(0.2 mg/kg) or pentazocine(0.5 mg/kg) 
allowed for a significant reduction in the mean dosage of midazolam 
required to produce satisfactory sedation when compared with trials, 
where  midazolam  was  used  alone.  Inadvertent  overdosage  with 
midazolm is prevented as the onset of sedation and its end-point are 
more obvious.
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12.  Van  den  Berg  AA,  Montoya  –  Pelaez  LF,  Halliday  EM, 
Hassan  I,  Baloch  MS  Department  of  Anesthesia,  Riyadh, 
Kingdom of Saudi Arabia.
              Compared the perioperative analgesic  and recovery 
characteristics  of  equipotent  doses  of  tramadol,  pethidine  and 
nalbuphine(3.0  mg  kg-1  nd  0.3  mg  kg-1  respectively)  with 
placebo(saline0.02 ml kg-1)given at induction of anaesthesia.
Equipotent dose of tramadol, pethidine and nalbuphine (3.0 mg kg-
1,1.5mg kg-1  and 0.3  mg kg-1  respectively)  with  placebo (saline 
0.02  ml  kg-1)  given  t  induction  of  anaesthesia  in  152  ASA.  1 
children  and  young  adults  undergoing  tonsillo-adenoidectomy. 
Pethidine  and  nalbuphine  reduced  the  intra-operative  esmolol 
requirement  more  significantly  (p  <  0.025  and  p  <  0.005 
respectively) and the need for need for treatment during recovery 
was  only  opioids  (p  <  0.005each).  These  results  suggest  that 
pethidine 1.5 mg/kg and nalbuphine 0.3 mg/kg given with induction 
of  anaesthesia  provide  better  analgesia  during  and  after 
tonsilloadenoidectomy than does tramadol 3.0mg/kg.he the time to 
recovery was delay with pethidine suggests a greater safety profile of 
nalbuphine and tramadol.
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MATERIALS AND METHODS
This study was done at Govt.  Rajaji Hospital Madurai.  100 
patients belonged to ASA grade I  & II with age of 20-60 years 
underwent elective infra umbilical surgeries were chosen.  
Exclusion Criteria: 
 Patients with spinal deformities, 
 Local skin sepsis, 
 Bleeding disorders and 
 Psychiatric illness 
Informed consent obtained after explaining the procedure.
Preanaesthetic  assessment  done  to  find  out  systemic  illness 
complicating anaesthesia.  
Premedication: inj. atropine 0.02mg/kg given 45minutes prior to 
surgery. No narcotic premedication.  The patients were explained 
about the 10 point visual analogue of pain scale. The patients were 
randomly chosen into two groups. 
Group A:
Received 15 ml of 0.5% bupivacaine with nalbuphine 10mg.
Group B:
Received 15 ml of 0.5% bupivacaine alone.
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 The following equipment’s kept ready before administering 
epidural anaesthesia.
Boyles machine with 02 source.
Working Laryngoscope and appropriate size ET tubes.
Suctioning  apparatus,
Vasopressors.
All emergency drugs.
TECHNIQUE 
An  intravenous  line  with  dextrose  normal  saline  started. 
Base line recording of pulse rate, blood pressure, respiratory rate 
and oxygen saturation noted down.  Patients were  placed in  the 
right lateral position on a horizontal table with head supported by a 
pillow.
Contents of epidural tray:
• Sponge holding forceps 
• Sterile gauze pieces
• Bowl with antiseptic solutions 
• Sterile towels 
• 5ml syringe with 24 G-needle  
• 16 G-huber point  Tuohy needle
• 10ml glass syringe with freely moving piston
49
• 1ml insulin syringe
• Nalbuphine ampoule 
• Sterile water for injection
• 0.5% bubivacaine vial
After  thorough  aseptic  precaution  L1-L2  or  L2-L3  Space 
located and using a 16 gauge Huber point Tuohy needle epidural 
space  was  identified  with  loss  of  resistance  technique.  Epidural 
catheter was inserted and fixed.
Aspiration was done to rule out subarachnoid or intravascular 
placement of the catheter.  A test dose of 2 ml of 1% lignocaine 
with 10 microgram of adrenaline was injected through the catheter 
and  finally  the  total  dose  of  15  ml  of  0.5%  bupivacine  with 
injection  nalbuphine  was  injected  through  the  catheter  and  the 
patients were positioned for the surgery.
 The level of sensory blockade was assessed every 2minutes. 
The time taken for level of block at T10 and the maximum time for 
maximum level of block noted down.  The time taken for grade 3 
motor block noted down.  Surgeons asked to proceeded the surgery 
only after the maximum level of blockade was established.  The 2 
segment regression time was noted.  The pulse rate, blood pressure, 
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respiratory  rate  were  monitored  every  5minutes.   Continuous 
oxygen  saturation  monitoring  done.   A  fall  in  systolic  blood 
pressure   by  20%  from  the  base  line  value  was  considered  as 
hypotension  and  managed  with  IV  fluids,  oxygen  and  inj. 
Ephedrine in incremental doses. At end of surgery  patients were 
observed in the recovery room for further two hours and sent to 
postoperative ward.  The level of consciousness assessed ever ½ 
hour and graded according to the sedation score.
Patients were asked to mark a point scale on the 10 point visual 
analogue  scale  of  pain  according  to  the  intensity  of  pain.   The 
observation was done every 30 minutes.  The pain relief is graded 
according to VAPS as follows.
VAPS Quality of analgesia
0-1 Excellent
1-4 fair
4-6 good
6-8 slight
8-10 no relief
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DURATION OF ANALGESIA
The duration of analgesia was taken as the period from the 
time of giving epidural analgesia till the patient’s first requirement 
of  systemic analgesic  medication.   Supplementary analgesia  was 
given when VAPS more than 6.
SEDATION SCORE LEVEL
The level of sedation assessed every 30minutes and graded 
according to the sedation score.  (Brain and Ready)
0- fully awake
1- Normal sleep
2- Drowsy, arousable on touch
3- Drowsy arousable to painful stimuli
4- Somnolent.
The  side  effects  due  to  Nalbuphine  like  nausea,  vomiting, 
pruritis, urinary retention were noted down.  Comparison between 
group A and group B were done using students ‘t’ test and the level 
of significance was taken below 0.05.
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RESULTS
VARIABLES AFFECTING COMPARABILITY BETWEEN THE 
STUDY GROUPS
1.  AGE AND DURATION OF THE PROCEDURE AMONG THE STUDY GROUPS
STUDY GROUPS N MEAN S.D S.E
T- TEST
(P VALUE)
AGE OF 
THE 
PATIENT
STUDY GROUP 
(BUPI+ NALBU)
50 43.26 7.645 1.081
0.974CONTROL (BUPI)
50 43.20 10.768 1.523
1A. AGE DISTRIBUTION OF STUDY POPULATION
STUDY GROUPS
FREQUENCY PERCENT
X2 TEST 
(P VALUE)
STUDY GROUP 
(BUPI+ NALBU)
20- 30 YRS 4 8.0
0.792
30- 40 YRS 13 26.0
40- 50 YRS 25 50.0
50- 60 YRS 8 16.0
TOTAL 50 100.0
CONTROL (BUPI) 20- 30 YRS 8 16.0
30- 40 YRS 12 24.0
40- 50 YRS 19 38.0
50- 60 YRS 10 20.0
>60 YRS 1 2.0
TOTAL
50 100.0
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2. SURGERIES PERFORMED AMONG THE GROUPS
STUDY GROUPS FREQUENCY PERCENT
STUDY GROUP 
(BUPI+ NALBU)
TVH 5 10.0
HERNIATOMY/RAPHY 18 36.0
VARICOSE VEINS 13 26.0
APPENDICECTOMY 11 22.0
BELOW KNEE 
AMPUTATION
1 2.0
SSG 2 4.0
TOTAL 50 100.0
CONTROL 
(BUPI)
TVH 4 8.0
HERNIATOMY/RAPHY 22 44.0
VARICOSE VEINS 9 18.0
APPENDICECTOMY 11 22.0
BELOW KNEE 
AMPUTATION
3 6.0
SSG 1 2.0
TOTAL
50 100.0
CHI SQUARE TEST: P VALUE=0.766
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3. GROUP STATISTICS
STUDY GROUPS N MEAN S.D S.E
INDEPENDENT 
T-TEST 
(P VALUE)
DURATION OF 
PROCEDURE
STUDY GROUP 
(BUPI+ NALBU)
50 61.48 7.538 1.066
0.273
CONTROL (BUPI) 50 63.00 6.171 .873
BASELINE 
SYSTOLIC BP
STUDY GROUP 
(BUPI+ NALBU)
50 118.12 16.529 2.338
0.276
CONTROL (BUPI) 50 121.32 12.353 1.747
BASELINE 
PULSE 
RATE(5MIN)
STUDY GROUP 
(BUPI+ NALBU)
50 80.56 6.276 .888
0.858CONTROL (BUPI)
50 80.34 6.022 .852
4. VARIABILITY OF THE STUDY CHARACTERS
N MEAN S.D S.E
INDEPENDENT T 
TEST 
(P VALUE)
TIME OF ONSET 
OF BLOCK
STUDY GROUP 
(BUPI+ NALBU) 50 5.22 1.234 .174 0.000
CONTROL (BUPI) 50 9.52 1.446 .205
ONSET OF 
GRADE III 
MOTOR BLOCK
STUDY GROUP 
(BUPI+ NALBU) 50 7.80 1.471 .208 0.000CONTROL (BUPI) 50 12.84 1.390 .197
TWO SEGMENT 
REGRESSION TIME
STUDY GROUP 
(BUPI+ NALBU) 50 70.14 6.138 .868 0.009
CONTROL (BUPI) 50 67.00 5.544 .784
DURATION OF 
ANALGESIA
STUDY GROUP 
(BUPI+ NALBU) 50 287.40 29.054 4.109 0.000
CONTROL (BUPI) 50 37.64 18.307 2.589
VISUAL 
ANALOGUE SCORE
STUDY GROUP 
(BUPI+ NALBU) 50 1.86 .756 .107 0.000
CONTROL (BUPI) 50 7.22 1.447 .205
SEDATION SCORE STUDY GROUP 
(BUPI+ NALBU) 50 0.46 0.503 0.071 0.000
CONTROL (BUPI) 50 0 0 0
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5. RESPIRATORY RATE AND OXYGEN SATURATION 
CHANGE DURING THE PROCEDURE
STUDY GROUPS
N MEAN S.D S.E
INDEPENDENT 
T-TEST (P 
VALUE)
RESPIRATORY 
RATE
STUDY GROUP 
(BUPI+ NALBU)
50 14.08 .877 .124
0.362
CONTROL (BUPI) 50 14.24 .870 .123
OXYGEN 
SATURATION
STUDY GROUP 
(BUPI+ NALBU)
50 98.80 .881 .125
0.000
CONTROL (BUPI) 50 97.28 .904 .128
6. SYSTOLIC BLOOD PRESSURE VARIABILITY DURING THE PROCEDURE
SYSTOLIC BP (5MIN)
SYSTOLIC BP 
(15MIN)
SYSTOLIC BP 
(30MIN)
SYSTOLIC BP 
(45MIN)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTRO
L (BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTRO
L (BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTRO
L (BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTRO
L (BUPI)
N 50 50 50 50 50 50 50 50
MEAN 118.12 121.32 114.84 100.40 111.96 113.54 112.72 120.86
STD. DEVIATION 16.529 12.353 11.809 11.249 9.454 13.852 9.439 12.746
S.E 2.338 1.747 1.670 1.591 1.337 1.959 1.335 1.802
INDEPENDENT T-
TEST (P VAL)
0.276 0.000 0.507 0.000
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7. PULSE RATE VARIABILITY DURING THE PROCEDURE
PULSE RATE (5MIN)
PULSE RATE 
(15MIN)
PULSE RATE 
(30MIN)
PULSE RATE 
(45MIN)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTROL 
(BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTROL 
(BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTROL 
(BUPI)
STUDY 
GROUP 
(BUPI+ 
NALBU)
CONTROL 
(BUPI)
N 50 50 50 50 50 50 50 50
MEAN 80.56 80.34 74.38 89.04 72.40 91.98 72.22 92.32
S.D 6.276 6.022 5.893 7.640 5.753 6.862 5.486 6.844
S.E .888 .852 .833 1.080 .814 .970 .776 .968
INDEPENDEN
T T-TEST
(P VAL)
0.858 0.000 0.000 0.000
57
Complications
50 100.0
38 76.0
11 22.0
1 2.0
50 100.0
AbsentValid
Absent
Hypotension
Vomitting
Total
Valid
Study groups
Study group
(Bupivacaine+
Nalbuphine)
Control (Bupivacaine)
Frequency Percent
Visual analogue score
18 36.0 36.0 36.0
21 42.0 42.0 78.0
11 22.0 22.0 100.0
50 100.0 100.0
1 2.0 2.0 2.0
6 12.0 12.0 14.0
11 22.0 22.0 36.0
7 14.0 14.0 50.0
13 26.0 26.0 76.0
12 24.0 24.0 100.0
50 100.0 100.0
1
2
3
Total
Valid
4
5
6
7
8
9
Total
Valid
Study groups
Study group
(Bupivacaine+
Nalbuphine)
Control (Bupivacaine)
Frequency Percent Valid Percent
Cumulative
Percent
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OBSERVATION AND RESULTS
Patients in both groups were comparable in age, duration, the 
site and type of surgery and  baseline parameters at the starting of 
procedure.   (Table 1,2,&3).  The observation recorded in this study 
are given as follows.
Results of Study characters and baseline measurement.
Age: Group A: The mean of 43.26 
Group B: The mean of 43.20 
‘t’ test (p value) 0.974
Age distribution  : t test is 0.792
Surgery performed : 0.766  (chi-square) 
Duration of procedure :   Group    A    B   t
61.48     63 0.273
Systolic BP  118.12    121.32 0.276 
Pulse Rate 80.56      80.34 0.858
< 0.05 insignificant
There were statistically no significant difference between mean age 
distribution, surgery performed duration of procedure and baseline 
parameters in both groups.
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RESULTS  OF  VARIABLES  OF  STUDY  CHARACTERS 
BETWEEN 2 GROUPS
The significance between the study and control groups was tested 
using the standard error of difference between the means
TIME OF ONSET OF SENSORY BLOCK (Table. 4)
In  group  A the  minimum time was 3  minutes  and  maximum 8 
minutes with a mean time of 5.22.
In group B the minimum time was 6 minutes and maximum 12 
minutes with a mean time of 9.52 minutes. 
R. Fournier, et al. Oct 1998 studied and reported the administration 
of  intrathecal  nalbuphine resulting in  a  significantly  faster  onset 
related with the time to the lowest pain score (18 + 11 VS 66 + 75 
minutes, P < 0.001)
In  the  study  also  rapid  onset  in  group  A  patients  is  due  to 
synergistic effect of nalbuphine and bupivacaine.
TIME OF ONSET OF MOTOR BLOCK(Grade 3)
All patients both groups developed Grade 3 Motor Block. The time 
latency  for  complete  blockade  was  taken  as  the  onset  of  motor 
block.
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In group A the minimum time was 5 minutes and maximum 10 
minutes with a mean time of 7.8.
In group B the minimum time was 9 minutes and maximum 15 
minutes with a mean time of 12.84 minutes. 
Since actual  difference between the mean is 5.04 – the study is 
significant (P < 0.000)
2 SEGMENT REGRESSION TIME (Table 4)
In the group A the regression time was the range of 60-83 minutes 
with mean of 70.14.
In the group A the regression time was the range of 54-84 minutes 
with mean of 67 with P < 0.009 which is significant. 
QUALITY OF ANALGESIA
The minimum VAPS was 1 and maximum 3 in Group A in 
the mean of 1.86.
In group B the quality of analgesia was not assessed since all 
of them received postoperative narcotic supplementation after the 
surgery.
In group A the quality of analgesia was fair in 30 (85.7%) 
patients and good in 5 (14.3%).
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Supported  by  the  study  of  Donadoni  R.  et  al  1988  in  which 
concluded that nalbuphine was far superior in onset duration and 
quality of pain relief in orthopaedic surgeries when compared to 
pethidine. 
DURATION OF SURGERY
In Group A the mean duration of surgery was 61.48 minutes, 
and 63 minutes in Group B. t value is 0.27.
SEDATION
In Group A 23 patients had sleep resembling natural sleep 
with sedation score of and 27 patients with sedation score of 1 with 
the mean of 0.46 (p value 0.000) which is statically significant.
In Group B all patients were awake.
KC 1983 studied the role of epidural analgesic and sedatives 
in the  management of  pain and agitation in which he compared 
nalbuphine with other narcotics. 
RESPIRATORY RATE
Respiratory rate< 10/ minute was not noted in any of patients. 
OXYGEN SATURATION
Measured by pulse oximetry was maintained above 95% in 
all patients.
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Group A 98.8
Group B 97.2
t test (p value is 0.000) which is significant
CHANGES BLOOD PRESSURE.
Time in minutes Group A Group B t value
5 118.12 100.4 0.276
15 114.84 100.4 0.000
30 119.6 113.54 0.05
45 112.72 120.86 0.000
There  is  significance  in  BP  maintenance  in  group  A 
throughout the procedure where as in group B it falls below the 
base line value after 5 minutes and 15 minutes and then raises after 
30 min and 45 minutes.
CHANGES PULSE RATE.
Time in minutes Group A Group B t value
5 80.6 80.3 0.8
15 74 89 0.000
30 72 92 0.000
45 72 92 0.000
No Hypotension occurred in group A and in group B 11 patients 
have  hypotension.  In  contrast  to  pentazocine  and  butorphanol, 
nalbuphine  does  not  increase  systolic  blood  pressure  and 
pulmonary  arterial  pressure,  heart  rate  (or)  atrial  filling pressure 
(Lee et al; 1976) 
SIDE EFFECTS
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NAUSEA AND VOMITING occurred in 1 patient in group B.
URINARY RETENTION could not be studied as the patients were 
catheterized at the end of surgery.
Parker  et  al  studied  the  interaction  between  nalbuphine  and 
hydromorphone  and  concluded  that  the  combination  of 
hydromorphone 0.075 mg/ml and nalbuphine 0.04mg/ml resulted in 
lower nausea score  and decreased incidence of  urinary retention 
compared with hydromorphone alone.   
PRURITIS:  No  patient  has  pruritis  in  the  post  operative 
period in group A and in group B.
DROWSINESS: In group A no patients had sedation score of 
more than one.  In group ‘B’ all the patients were awake.
RESPIRATORY DEPRESSION: did not occur in any of the 
patients.
Nalbuphine  10  to  20mg  reverses  postoperative  ventilation 
caused  by  fentanyl  but  maintain  analgesia  (Bailey  et  al  1987; 
molden Hawer et al, 1985)
Depression of ventilation is similar to that of morphine until 
30mg of nalbuphine is exceeded, after with no further depression of 
ventilation occurs (ceiling effect) (Gal et al; 1982)  
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DISCUSSION
Epidural administration of narcotics for post surgical analgesia is 
becoming increasingly popular with more practitioners. This is clearly 
because  this  modality  of  analgesia  has  unique  advantages  over 
conventional,  intermittent  IV/IM administration  of  narcotics.  Patients 
given epidural narcotics have fewer respiratory complications and can 
be mobilized sooner in the postoperative period.
However,  the  drug  that  has  been  utilized  most  widely,  i.e., 
morphine,  produces  distressing  side  effect  and sometimes  potentially 
lethal complications like delayed and prolonged respiratory depression*. 
several other narcotics have been evaluated in order to identify  a drug 
that  affords  as  efficient  analgesia  but  causes  much  less  respiratory 
depression  when  given  epidurally  for  epidural  use.  The 
agonist/antagonist narcotic agent can be expected to offer some scope in 
this respect, since the respiratory depression reaches ceiling level* with 
higher receptor occupancy at higher dose of the drug. Apart from this 
these  drugs  are  not  as  potent  as  morphine  in  causing  respiratory 
depression*.  In  this  study,  neither  bradypnoea  nor  frank  respiratory 
depression  was encountered.
The agonist – antagonist class of drugs have the advantage that 
they trend to release less  histamine and thus cause less hypotension. 
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Similarly, they also have less abuse potential. Thus nalbuphine being an 
agonist antagonist has all these advantages.
 Epidurally  administered  nalbuphine  reported  satisfactory 
outcome with regard to quality of analgesia  and incidence of  serious 
complications*.  In  the  present  study  also  there  was  no  respiratory 
depression and nausea and vomiting, however  PaCO2 level were not 
monitored.
The  quality  of  analgesia  was  good  in  patients  given  epidural 
nalbuphine. At the end of any period of observation, more patients from 
group A had zero points on the VAS as compared to those from Group 
B. It was found that none of the Group B patients had zero pain score 
after 24 hrs. This could be because epidurally given nalbuphine could no 
longer provide pain relief after 24 hrs. While those in Group B could 
have demanded and obtained analgesia shortly before pain score was 
measured.
No  troublesome  side  effect  were  encountered  either  in  the 
experimental or in the control group .Some patients in Group A were 
very drowsy. After allowing them to sleep for half an hour, they were 
sufficiently  awake  to  use  the  visual  analog  scale.  None  required 
catheterization  of  the  urinary  bladder.  None  experienced  itching, 
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vomiting,  shivering ,  although other studies have reported these with 
extradural fentanyl, dimorphine and other opiates*.
 It was one of  the explicit aims in the present study to measure 
the duration of analgesia  in the epidural group, It was observed that 
patients demanded analgesia at the end of 7 hours (5.5 mean). In the 
study by Weksler et al epidural nalbuphine provided a mean duration of 
analagesia for 8 hrs and 45 min(±2.25 hrs)*.  
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SUMMARY  
In  this  study,  epidural  NALBUPHINE  was  evaluated  as  an 
analgesic  and its influence on BP, PR, oxygen saturation.  Fifty adult 
patients undergoing infra umbilical surgery electively were included in 
the study. All were fit  patients belonging to ASA category I/II.  Fifty 
patients who were matched for age, type of surgery, duration of surgery 
and baseline  parameters  received analgesia  according to  the  stranded 
protocol. They were control groups. Injection into epidural space in the 
study group was given before starting of surgery. Pain was measured on 
a visual analogue scale and PR, oxygen saturation by pulse oxymetry.
When  nalbuphine  given  epidurally  has  provided  excellent 
analgesia in the immediate intraoperative and postoperative period. As 
reported  in  several  studies  Nalbuphine  offered  good  cardiovascular 
stability  without  the  risk  of  several  respiratory  depression  though  it 
produce sedation in some of our patients. Our patients had good overall 
analgesia with improved respiratory function.
Nalbuphine when used with Bupivacaine decrease the onset time 
of sensory blockade and time taken for grade3 motor block. It produces 
post operative analgesia for period of 4- 7 hours with a mean duration of 
5.5 hours.
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No  incidence  of  nausea,  vomiting,  shivering  were  noted  with 
epidural nalbuphine.
Nalbuphine when combined with Bupivacaine hastens the onset 
of  sensory  block.  It  is  speculated  that,  with  studies  invoking  larger 
sample of patients, nalbuphine may well emerges an alternative to other 
opoids for epidural use.  
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CONCLUSION
This prospective, randomized, single blind study , wherein Nalbuphine 
in a dose of 10 mg  was added epidurally to 0.5% Bupivacaine – for 
infra umbilical surgeries concludes that 
“  epidural  Nalbuphine  hastens  the  onset  of  both  sensory  and 
motor blockade and significantly prolonged the duration of anaesthesia 
and postoperative analgesia, with stable haemodynamics”
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PROFORMA
Name : Age / Sex  : IP No. :
Address :  
Diagnosis  : Surgery  : DOA :  Unit :
Anaesthesiologist : Surgeon :
Pre Anaesthetic Assessment Preoperative Investigations
General Condition Urine Albumin
Sugar
Weight Hb%
CVS BT
RS CT
PR Blood Urea
BP Blood sugar
Spines Serum creatinine
Airway Blood grouping
ASA status Chest  X ray
ECG
Premedication
Drug Dose Route Time
Technique of Anaesthesia :  Lumbar epidural 
Position  :  Right lateral Space :  L1 – L2 Approach : Midline
75
Needle  : 16 G Catheter :  10 cm  Drug : Bubivacaine
  0.5%(15ml) 
Time of Admission :    Time of Onset :   Sensory level :
Time of two segment regression :
Total duration of Surgery
Grade I Motor block
Motor level (Modified Bromage scale)
(0- No motor loss,  1 – Inability to flex hip  2 – Inability to flex the knee
3 – Inability to flex the ankle)
Time
Level
Sedation score (Three point ordinal scale)
(0-  awake,   1  –  Drowsy  but  arousal,  2  –  sleeping,   3  – 
unarousable, 5 – No response to loud voice,  6 – No response to pain)
Time
Score
Time to get   first Analgesia :
VRS
Side effects & Complications :
1. Shivering
2. Pruritis
3. Nausea, vomiting
4. Respiratory depression
5. Hypotension
6. Bradycardia
76
77
78
79
STRUCTURE OF NULBUPHINE
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STRUCTURE OF BUPIVACAINE
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